Table 3.
Episodes of CMV infection or disease during the first 12 months in 88 CMV- seropositive (R+) lung transplant recipients
|
CMV infection or disease |
Oral ganciclovir 3 months |
Valganciclovir 3 months |
p-value |
|---|---|---|---|
| (n %) | n = 37 | n = 51 | |
| LTx, years |
2001-2003 |
2004-2006 |
|
| No CMV, n (%) |
17 (46) |
39 (76) |
|
| CMV infection/disease, n (%) |
20 (54) |
12 (24) |
0.003 |
| CMV disease -Total n (%) |
12 (33) |
10 (20) |
0.170 |
| -Severe |
0 |
2 (4) |
0.262 |
| -Moderate |
8 (22) |
5 (10) |
|
| -Mild |
4 (11) |
3 (6) |
|
| Asymptomatic CMV inf., n (%) |
8 (22) |
2 (4) |
0.005 |
| Prolonged CMV episode, n (%) |
1 (3) |
2 (4) |
0.756 |
| Gastrointestinal CMV inf., n (%) |
2 (5) |
2 (4) |
0.741 |
| Ganciclovir resistance, n (%) |
0 |
1 (2) |
0.392 |
| Onset of CMV inf/disease, days, |
|
|
0.188 |
| Median, mean |
174,163 |
154,136a |
|
| (range) | (100-270) | (23-201a) |
aOnset of CMV infection was 62 days after transplantation for one patient who probably had a GCV resistant virus. Two patients had no or inadequate CMV prophylaxis owing to renal failure. Onset of CMV infection for these two patients was 23 days and 32 days after transplantation. For the remaining individuals in the VGCV group the onset of CMV infection/disease was on average 168 days after transplantation (range: 147 – 201 days).